Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety

Giovanni Maconi, Deborah Camatta, Rosanna Cannatelli, Francesca Ferretti, Anna Carvalhas Gabrielli, Sandro Ardizzone Gastroenterology Unit, Department of Biomedical and Clinical Sciences FBF – L.Sacco, University Hospital, Milan, ItalyCorrespondence: Giovanni MaconiGastroenterology Unit, D...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maconi G, Camatta D, Cannatelli R, Ferretti F, Carvalhas Gabrielli A, Ardizzone S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	budesonide mmx ulcerative colitis efficacy effectiveness safety Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/ebee08982e6e4a13aa4ae5fb39b5cb2a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ebee08982e6e4a13aa4ae5fb39b5cb2a
record_format	dspace
spelling	oai:doaj.org-article:ebee08982e6e4a13aa4ae5fb39b5cb2a2021-12-02T14:25:56ZBudesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety1178-203Xhttps://doaj.org/article/ebee08982e6e4a13aa4ae5fb39b5cb2a2021-04-01T00:00:00Zhttps://www.dovepress.com/budesonide-mmx-in-the-treatment-of-ulcerative-colitis-current-perspect-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XGiovanni Maconi, Deborah Camatta, Rosanna Cannatelli, Francesca Ferretti, Anna Carvalhas Gabrielli, Sandro Ardizzone Gastroenterology Unit, Department of Biomedical and Clinical Sciences FBF – L.Sacco, University Hospital, Milan, ItalyCorrespondence: Giovanni MaconiGastroenterology Unit, Department of Biomedical and Clinical Sciences, ASST Fatebenefratelli-Sacco University Hospital, University of Milan, ItalyTel +39 02 39043164Fax +39 02 39042232Correspondence Email giovanni.maconi@unimi.itAbstract: Budesonide MMX is a low bioavailability corticosteroid oral once-daily formulation, which has a controlled rate of release throughout the colon, thanks to the multimatrix (MMX) formulation. It has been available for a decade in the USA and Europe for the induction of remission in patients with active, mild to moderate ulcerative colitis, particularly for those not responsive to mesalamine. The efficacy of budesonide MMX in this setting has been assessed by registrative randomized controlled trials showing a higher rate of clinical and endoscopic remission at 8 weeks compared with placebo, mostly in patients with proctosigmoiditis and left-side colitis. Since it is available in our therapeutic armamentarium, a few studies have confirmed the effectiveness of budesonide MMX also in real-life, highlighting the high rate of clinical response and remission and the high safety profile. In the present review, we summarise clinical trials and real-life results of budesonide MMX, assessing its use and predictors of response and non-response in real-life.Keywords: budesonide MMX, ulcerative colitis, efficacy, effectiveness, safetyMaconi GCamatta DCannatelli RFerretti FCarvalhas Gabrielli AArdizzone SDove Medical Pressarticlebudesonide mmxulcerative colitisefficacyeffectivenesssafetyTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 285-292 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	budesonide mmx ulcerative colitis efficacy effectiveness safety Therapeutics. Pharmacology RM1-950
spellingShingle	budesonide mmx ulcerative colitis efficacy effectiveness safety Therapeutics. Pharmacology RM1-950 Maconi G Camatta D Cannatelli R Ferretti F Carvalhas Gabrielli A Ardizzone S Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
description	Giovanni Maconi, Deborah Camatta, Rosanna Cannatelli, Francesca Ferretti, Anna Carvalhas Gabrielli, Sandro Ardizzone Gastroenterology Unit, Department of Biomedical and Clinical Sciences FBF – L.Sacco, University Hospital, Milan, ItalyCorrespondence: Giovanni MaconiGastroenterology Unit, Department of Biomedical and Clinical Sciences, ASST Fatebenefratelli-Sacco University Hospital, University of Milan, ItalyTel +39 02 39043164Fax +39 02 39042232Correspondence Email giovanni.maconi@unimi.itAbstract: Budesonide MMX is a low bioavailability corticosteroid oral once-daily formulation, which has a controlled rate of release throughout the colon, thanks to the multimatrix (MMX) formulation. It has been available for a decade in the USA and Europe for the induction of remission in patients with active, mild to moderate ulcerative colitis, particularly for those not responsive to mesalamine. The efficacy of budesonide MMX in this setting has been assessed by registrative randomized controlled trials showing a higher rate of clinical and endoscopic remission at 8 weeks compared with placebo, mostly in patients with proctosigmoiditis and left-side colitis. Since it is available in our therapeutic armamentarium, a few studies have confirmed the effectiveness of budesonide MMX also in real-life, highlighting the high rate of clinical response and remission and the high safety profile. In the present review, we summarise clinical trials and real-life results of budesonide MMX, assessing its use and predictors of response and non-response in real-life.Keywords: budesonide MMX, ulcerative colitis, efficacy, effectiveness, safety
format	article
author	Maconi G Camatta D Cannatelli R Ferretti F Carvalhas Gabrielli A Ardizzone S
author_facet	Maconi G Camatta D Cannatelli R Ferretti F Carvalhas Gabrielli A Ardizzone S
author_sort	Maconi G
title	Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
title_short	Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
title_full	Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
title_fullStr	Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
title_full_unstemmed	Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
title_sort	budesonide mmx in the treatment of ulcerative colitis: current perspectives on efficacy and safety
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/ebee08982e6e4a13aa4ae5fb39b5cb2a
work_keys_str_mv	AT maconig budesonidemmxinthetreatmentofulcerativecolitiscurrentperspectivesonefficacyandsafety AT camattad budesonidemmxinthetreatmentofulcerativecolitiscurrentperspectivesonefficacyandsafety AT cannatellir budesonidemmxinthetreatmentofulcerativecolitiscurrentperspectivesonefficacyandsafety AT ferrettif budesonidemmxinthetreatmentofulcerativecolitiscurrentperspectivesonefficacyandsafety AT carvalhasgabriellia budesonidemmxinthetreatmentofulcerativecolitiscurrentperspectivesonefficacyandsafety AT ardizzones budesonidemmxinthetreatmentofulcerativecolitiscurrentperspectivesonefficacyandsafety
_version_	1718391403217682432

Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety

Ejemplares similares